Funding
← Back to your selection

Novo Holdings

Activity from announced rounds

All recorded activity

Novo Holdings manages the Novo Nordisk Foundation’s investment assets and invests in healthcare and life sciences across development stages.

Investment focus

The foundation-owned holding and investment company combines a broad long-term asset portfolio with dedicated healthcare and life-sciences investment teams. Its activities include seed, venture, planetary health and principal investments.

Activity recorded by RoundOS

Recorded financing includes AnaCardio’s heart-failure drug development, Adcendo’s antibody-drug conjugates, Terremoto’s small-molecule programs and Crystalys’ gout treatment candidate. These entries show selected therapeutic investments in the database, spanning different disease areas and clinical programs.

Sources
Rounds participated in
7
Confirmed lead rounds
4
3 roles undisclosed
New companies
6
First participation on record · 1 follow-on
Funding in participating rounds
$774.6M
7 disclosed · full round size, not this investor’s share

By stage

Series C+3
Series B2
Seed1
Series A1

By primary sector

Biotech7

By country

Denmark3
United States2
Sweden1
United Kingdom1

Rounds

7 in all activity
OMass Therapeutics

OMass Therapeutics develops small-molecule medicines for endocrine and immune diseases using a platform that measures drug targets in their biological surroundings.

$310MSeries C
Lead
AnaCardio

AnaCardio develops oral medicines intended to improve heart muscle contraction in people with heart failure.

€62.5MSeries B
Lead
Crystalys Therapeutics

Crystalys Therapeutics develops dotinurad, an oral URAT1 inhibitor for treating gout

$130MSeries B
Role not disclosed
Terremoto Biosciences

Develops highly targeted, small molecule medicines for cancer and rare diseases

$108MSeries C
Role not disclosed
Adcendo

Adcendo develops antibody-drug conjugates that deliver cancer drugs to tumor-associated targets, with clinical programs in solid tumors and soft tissue sarcoma.

$75MSeries C
Role not disclosed